PharOS has entered a strategic partnership with Purposeful, significantly investing in the startup and acquiring partial shares, aimed at advancing innovative drug development solutions for rare diseases.

Target Information

Purposeful, a startup founded in 2018 by a team comprising Dr. George Drakakis, Mr. Charalambos Chomenidis, Dr. Georgia Tsiliki, and Prof. Aristides Dokoumetzidis, specializes in chemoinformatics, bioinformatics, and software technologies. This experienced team has a strong background in biostatistical analysis, biological activity prediction, drug mechanism of action extrapolation, and complex biological and chemical data modeling. Purposeful's primary mission is to identify alternative uses for existing medications through advanced computational intelligence workflows, with the overarching goal of developing cures for rare diseases.

Over the past five years, Purposeful, backed by Metavallon VC, has made significant strides in smart manufacturing and prioritization strategies. The company has also been pioneering innovative pharmaceutical products targeting disorders such as Fragile X, Glioblastoma, Pitt-Hopkins, and Acrodysostosis. Many of these projects have progressed to successful in vitro and in vivo experiments, international patent applications, and initial clinical studies. The organization has established collaborations with several pharmaceutical firms, research institutions, and international patient organizations, utilizing advanced machine learning algorithms within its intelligent drug repurposing methodology to substantially reduce drug development costs.

Industry Overview

The pharmaceutical industry in Greece has been undergoing a transformational phase, especially with the recent emphasis on innovative drug development and biotechnology. Greece's richness in biodiversity, combined with a growing emphasis on research and developmen